Main Page | Peptides | Polypeptide Analog of Tirzepatide
Polypeptide Analog of Tirzepatide
Our experimental drug is a long-acting protein-based dual agonist of GLP-1 and GIP receptors, produced through genetic engineering using Escherichia coli cells. This hypoglycemic agent is being developed for the treatment of type 2 diabetes and obesity.

Key Advantages:

• Effective blood glucose reduction
• Significant weight loss promotion
• Convenient once-weekly administration

АUnlike the tirzepatide formulation under development in the United States, which uses amino acid modifications and fatty acid tail attachment for albumin binding to prolong circulation time, our molecule employs covalent fusion with a large inert polypeptide. This innovative approach slows renal filtration of the drug from blood plasma while maintaining complete immunological safety, as the inert polypeptide is non-immunogenic.

This proprietary method of extending the molecule’s duration of action provides strong patentability potential. The development of such anti-obesity medication is particularly promising and urgently needed, given projections that the global obese population will reach 1 billion people by 2025. Our technology represents a significant advancement in metabolic disease treatment, offering both therapeutic efficacy and manufacturing advantages.